MarketLens

What Do the Latest SUMMIT Trial Data Mean for Bezuclastinib

5 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What Do the Povorcitinib Trial Results Mean for Incyte

5 months ago

What Do Summit Therapeutics' Q4 Results Reveal About Its Financial Health

6 months ago

What Do Karyopharm's Mixed SENTRY Trial Results Mean for Myelofibrosis Treatment

5 months ago

Why is Thermo Fisher Betting Big on Clinical Trial Data

5 months ago

Beat AML® Study Provides New Data on 14-Day vs. 28-Day Venetoclax-Azacitidine Treatment in AML

Beat AML study data published in Blood compares 14-day vs 28-day venetoclax-azacitidine dosing in older AML patients, potentially informing shorter treatment regimens.

Stock News•1 months ago

SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study

Summit shares rose after updated HARMONi data showed ivonescimab survival benefit in NSCLC, and a new partnership with Arcus will test the drug in kidney cancer.

SMMT

Stock News•1 months ago

Kura Oncology: A Menin Inhibitor Launch With More Than One Way To Win

Kura Oncology positions ziftomenib as an AML combination backbone, supported by high remission rates and tolerability data. A robust cash position from Kyowa Kirin payments funds the pivotal KOMET-017...

KURA

Stock News•1 months ago

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

AbbVie's TEPKINLY + R2 was approved by the European Commission for relapsed/refractory follicular lymphoma, after a Phase 3 trial showed ~75% complete response and improved progression-free survival v...

ABBV